July 2026

Contents

Early access

• Merck announces alimatravir access programme ahead of AIDS 2026

Special reports

• AIDS 2026: Programme highlights to look out for

Conference reports

• AIDS 2026: Activists challenge US government’s claims to manage PEPFAR

• AIDS 2026: High efficacy continues in open label extensions to lenacapavir phase 3 PrEP studies

Antiretrovirals

• Drug interactions with islatravir (in combination with doravirine)

Paediatric care

• Updated US paediatric HIV guidelines include dolutegravir from birth

Activism & advocacy

• One Voice Charter raises awareness of patient rights for Black people living with HIV in London

• Book review: Living Well with HIV: a DIY guide

Other news

• All Wales HIV guidelines routinely exclude single tablet regimens as first-line ART